

# Considerations for Your Peer-to-Peer Review

If coverage is denied for your patient, the following checklist can serve as a guide for your peer-to-peer review, allowing you to explain why your preferred course of treatment is medically necessary.

**NOTE:** It is recommended that peer-to-peer attestation be completed by the prescribing clinician (eg, physician, PA, NP) who is treating the patient for the disease state. Additionally, this prescribing clinician may request that the insurer's peer reviewer be of the same specialty (eg, oncology).

Use of the resource does not guarantee that the insurance company will provide reimbursement, and is not intended to be a substitute for or an influence on the independent medical judgment of the health care provider. This is a guide and is not to be taken as a specific recommendation.

## INFORMATION TO GATHER AHEAD OF TIME



### Patient and policy information

- Name and date of birth of:
  - Patient
  - Primary insurance policy holder
- Insurance policy and group number

### Product information

- Indication statement
- Prescribing Information
- Relevant NDC number(s)
- ICD-10-CM codes
- Relevant HCPCS code(s) (miscellaneous or permanent J-codes depending on the medication's approval status)

### Explanation of why the first request was denied

- Gather and review documentation previously provided to the payer
  - Claim form and explanation of benefits (EOB), if claim was submitted
- Prior authorization request
- Letter of medical necessity, payer denial letter(s), and letter of appeal

**Have you already initiated an appeal? If so, be prepared with the details of the appeal.**

### Clinical documentation

- Summary of patient's diagnosis
- Details as to why the product is medically necessary for your patient
- Prior treatments and frequency
- Current laboratory reports
- Any additional patient-specific characteristics or medical records supporting the diagnosis and/or treatment

**Focus on specifics beyond severity, and provide supportive clinical data.**

# Considerations for Your Peer-to-Peer Review

## ADDITIONAL RESOURCES TO CONSIDER



### Relevant publications/data

- Peer-reviewed clinical trials
- National Comprehensive Cancer Network (NCCN) guidelines (if applicable)

### Supporting letters of medical necessity

Visit [DSAccessCentral4U.com](https://DSAccessCentral4U.com) for template letters.



For case-specific questions or additional information, please contact your local Daiichi Sankyo field reimbursement specialist, visit [DSAccessCentral4U.com](https://DSAccessCentral4U.com), or call 1-866-4-DSI-NOW (1-866-437-4669).

Abbreviations: HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.



AccessCentral4U™ is a trademark of Daiichi Sankyo Company, Limited.  
© 2025 Daiichi Sankyo, Inc. All rights reserved.  
PP-US-NP-2602 1/25